ELEV vs. IMUX, CRVO, ORMP, QNTM, EPIX, VXRT, ONCY, ANRO, ENTX, and ELUT
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Immunic (IMUX), CervoMed (CRVO), Oramed Pharmaceuticals (ORMP), Quantum Biopharma (QNTM), ESSA Pharma (EPIX), Vaxart (VXRT), Oncolytics Biotech (ONCY), Alto Neuroscience (ANRO), Entera Bio (ENTX), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry.
Elevation Oncology vs. Its Competitors
Immunic (NASDAQ:IMUX) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.
Immunic currently has a consensus price target of $7.50, indicating a potential upside of 689.47%. Elevation Oncology has a consensus price target of $2.62, indicating a potential upside of 616.89%. Given Immunic's stronger consensus rating and higher probable upside, research analysts plainly believe Immunic is more favorable than Elevation Oncology.
In the previous week, Immunic had 1 more articles in the media than Elevation Oncology. MarketBeat recorded 2 mentions for Immunic and 1 mentions for Elevation Oncology. Immunic's average media sentiment score of 0.12 beat Elevation Oncology's score of 0.00 indicating that Immunic is being referred to more favorably in the media.
51.8% of Immunic shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 4.6% of Immunic shares are held by company insiders. Comparatively, 8.1% of Elevation Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Elevation Oncology's return on equity of -74.68% beat Immunic's return on equity.
Immunic has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
Immunic is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Elevation Oncology beats Immunic on 8 of the 14 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:ELEV) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access